The 18 references in paper A. Bajtimerov R., G. Ahmadeeva N., I. Giljazova R., I. Hidijatova M., I. Tuktarova A., Je. Husnutdinova K., N. Demchuk D., R. Magzhanov V., T. Nasibulli R., А. Байтимеров Р., Г. Ахмадеева Н., И. Гилязова Р., И. Туктарова А., И. Хидиятова М., Н. Демчук Д., Р. Магжанов В., Т. Насибуллин Р., Э. Хуснутдинова К. (2015) “ИССЛЕДОВАНИЕ ВЛИЯНИЯ ПОЛИМОРФИЗМА ГЕНА COMT НА ХАРАКТЕР КЛИНИЧЕСКОГО ТЕЧЕНИЯ БОЛЕЗНИ ПАРКИНСОНА // THE ANALYSIS OF ASSOCIATION OF POLYMORPHIC VARIANTS OF THE GENE COMT WITH COURSE OF PARKINSON DISEASE AUT ITS SYMPTOMS” / spz:neicon:nevro:y:2013:i:3:p:22-27

1
Emre M., Aarsland D., Brown R. et al. Clinical diagnostic criteria for dementia associated with Parkinson disease. Mov. Disord.
(check this in PDF content)
2
07; 22: 1689—707. 2. Левин О.С., Федорова Н.В. Болезнь Паркинсона. М.; 2006.
(check this in PDF content)
3
Jellinger K., Kienzl E., Rumpelmair G., Riederer P., Stachelberger H., Ben-Shachar D., Yodium M.B. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J. Neurochem. 1992; 59: 1168—71.
(check this in PDF content)
4
Beck A.T., Ward C., Mendelson M. An inventory for measuring depression. Arch. Gen. Psychiatry. 1961; 4: 561—71.
(check this in PDF content)
5
Ханин Ю.Л. Краткое руководство по применению шкалы реактивной и личностной тревожности Ч.Д. Спилбергера. Л.: ЛНИИТЕК; 1976.
(check this in PDF content)
6
Mathew C. The isolation of high molecular weight eucariotic DNA. In: Walker J.M., ed. Methods in molecular biology. New York: Haman press; 1984; 2: 31—4.
(check this in PDF content)
7
Hoda F., Nicholl D., Bennett P., Arranz M., Aitchison K.J. et al. No association between Parkinson’s disease and low-activity alleles of catechol-O-methyltransferase. Biochem. Biophys. Res. Commun. 1996; 228: 780—4.
(check this in PDF content)
8
Yoritaka A., Hattori N., Yoshino H., Mizuno Y. Catechol-O-methyltransferase genotype and susceptibility to Parkinson’s disease in Japan. J. Neural Transm. 1997; 104: 1313—7.
(check this in PDF content)
9
Kunugi H., Kawada Y., Hattori M., Ueki A., Otsuka M., Nanko S. Association study of structural mutations of the tyrosine hydroxylase gene with schizophrenia and Parkinson’s disease. Am. J. Med. Genet. 1998; 81 (2): 131—3.
(check this in PDF content)
10
Bialecka M., Drozdzik M., Honczarenko K., Gawronska-Szklarz B., Stankiewicz J., Dabrowska E. et al. Catechol-O-methyltransferase and monoamino oxidase B genes and susceptibility to sporadic Parkinson’s disease in a Polish population. Eur. Neurol. 2005; 53: 68—73.
(check this in PDF content)
11
Xie T., Ho S.L., Li L.S.W., Ma O.C.K. G/A 1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson’s disease. Mov. Disord. 1997; 12: 426—7.
(check this in PDF content)
12
Syvänen A.C., Tilgmann C., Rinne J., Ulmanen I. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics. 1997; 7 (1): 65—71.
(check this in PDF content)
13
Wu R.M., Cheng C.W., Chen K.H., Lu S.L., Shan D.E., Ho Y.F., Chern H.D. The COMT L allele modifi es the association between MAOB polymorphism and PD in Taiwanese. Neurology. 2001; 56: 375—82.
(check this in PDF content)
14
Eerola J., Launes J., Hellström O., Tien ari P.J. Apolipoprotein E (APOE), PARKIN and catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic Parkinson’s disease in Finland. Neurosci. Lett. 2002; 330: 296—8.
(check this in PDF content)
15
Goudreau J.L., Maraganore D.M., Farrer M.J., Lesnick T.G., Singleton A.B., Bower J.H., Hardy J.A., Rocca W.A. Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson’s disease. Mov. Disord. 2002; 17 (6): 1305—11.
(check this in PDF content)
16
Morikawa N., Nakagawa-Hattori Y., Mizuno Y. Effect of dopamine, dimethoxyphenylethylamine, papaverine, nd related compounds on mitochondrial respiration and complex I activity. J. Neurochem. 1996; 66: 1174—81.
(check this in PDF content)
17
Hoogland J., de Bie R.M., Williams-Gray C.H., Muslimović D., Schmand B., Post B. Catecol-O-methyltransferase Val158Met and cognitive function in Parkinson’s disease. Mov. Disord. 2010; 25 (15): 2550—4.
(check this in PDF content)
18
Barnett J.H., Xu K., Heron J., Goldman D., Jones P.B. Cognitive effects of genetic variation in monoamine neurotransmitter systems: f population based study of COMT, MAOA, and 5HTTLPR. Am. J. Med. Genet. PB. 2011; 156: 158—67.
(check this in PDF content)